REG-Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Oculis Holding AG announced that management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference on July 10, 2026. The company plans to provide an update on its late-stage portfolio, including Privosegtor for optic neuropathies and Licaminlimab for dry eye disease, targeting a potential market opportunity of over $7 billion.
Key figures
- Potential market opportunity
- $7B+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.